Editor’s Note: The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC) and Best of ASCO® 2025 China (BOC/BOA) will be held on July 4–5 in Nanjing. This year’s event coincides with the 10th anniversary of the China Clinical Oncology Annual Research Progress publication—marking a key milestone in China's oncology journey. Over the past decade, the field has witnessed robust growth, and BOC/BOA has emerged as a vital academic bridge linking global innovations with local practice. This year’s conference will bring together leading experts from around the world to review the remarkable achievements of the past ten years and explore future directions in cancer care.In this exclusive interview with Oncology Frontier, Professor Jinming Yu—President of CSCO, Academician of the Chinese Academy of Engineering, and President of Shandong Cancer Hospital shares his reflections on the transformation of oncology in China and offers a forward-looking perspective on the nation’s cancer control strategy.
Oncology Frontier: Prof. Yu, the 2025 BOC/BOA Conference is about to take place, and it also marks the 10th anniversary of the China Clinical Oncology Annual Research Progress publication. Could you share what makes BOC/BOA unique, and what impact this decade-long publication has had on China’s anti-cancer efforts?
Prof. Jinming Yu: BOC/BOA is one of the most influential academic events in oncology, with its unique strength lying in its dual focus—bridging global frontiers while rooting itself in China’s clinical realities. Each year, the conference not only provides timely interpretations of groundbreaking studies presented at international meetings like ASCO, but also invites top domestic experts to analyze their relevance in the Chinese context. This dual approach ensures both rapid dissemination of global insights and meaningful integration with China’s clinical practice.
The China Clinical Oncology Annual Research Progress has grown alongside China’s rapidly advancing cancer control landscape over the past ten years. This annual publication has helped elevate Chinese research to the global stage and has become an important reference for guideline updates, new drug approvals, and future research planning. Many studies included in this publication have already been translated into clinical practice, significantly advancing the standardization and precision of cancer treatment in China.
Oncology Frontier: As President of CSCO, would you like to share a message for the upcoming BOC/BOA conference?
Prof. Jinming Yu: Over the years, BOC/BOA has grown into a flagship event for China’s oncology community. As we celebrate its 10th anniversary, the conference stands not only as a testament to past achievements but also as a call to shape the future. I hope this year’s gathering continues to serve as a vital bridge between Chinese and global academic exchange, allowing the world to hear more of China’s voice in cancer care. May our collective wisdom contribute to global health and advance cancer treatment to new heights. I wish the conference great success and look forward to working with colleagues to chart a new course in the fight against cancer.
Prof. Jinming Yu Shandong Cancer Hospital Academician of the Chinese Academy of Engineering, MD, PhD supervisor President, Chinese Society of Clinical Oncology (CSCO)
